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Abstract
Background: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune disorder of the central
nervous system (CNS). Its immunopathogenesis has been proposed to include early cerebrospinal fluid (CSF)
lymphocytosis, subsequent CNS disease restriction and B cell mechanism predominance. There are limited data
regarding T cell involvement in the disease. To contribute to the current knowledge, we investigated the complex
system of chemokines and cytokines related to B and T cell functions in CSF and sera samples from anti-NMDAR
encephalitis patients at different time-points of the disease. One patient in our study group had a long-persisting
coma and underwent extraordinary immunosuppressive therapy.
Methods: Twenty-seven paired CSF/serum samples were collected from nine patients during the follow-up period
(median 12 months, range 1–26 months). The patient samples were stratified into three periods after the onset of
the first disease symptom and compared with the controls. Modified Rankin score (mRS) defined the clinical status.
The concentrations of the chemokines (C-X-C motif ligand (CXCL)10, CXCL8 and C-C motif ligand 2 (CCL2)) and the
cytokines (interferon (IFN)γ, interleukin (IL)4, IL7, IL15, IL17A and tumour necrosis factor (TNF)α) were measured with
Luminex multiple bead technology. The B cell-activating factor (BAFF) and CXCL13 concentrations were determined
via enzyme-linked immunosorbent assay. We correlated the disease period with the mRS, pleocytosis and the levels of
all of the investigated chemokines and cytokines. Non-parametric tests were used, a P value <0.05 was considered to
be significant.
Results: The increased CXCL10 and CXCL13 CSF levels accompanied early-stage disease progression and pleocytosis.
The CSF CXCL10 and CXCL13 levels were the highest in the most complicated patient. The CSF BAFF levels remained
unchanged through the periods. In contrast, the CSF levels of T cell-related cytokines (INFγ, TNFα and IL17A) and IL15
were slightly increased at all of the periods examined. No dynamic changes in chemokine and cytokine levels were
observed in the peripheral blood.
Conclusions: Our data support the hypothesis that anti-NMDAR encephalitis is restricted to the CNS and that
chemoattraction of immune cells dominates at its early stage. Furthermore, our findings raise the question of
whether T cells are involved in this disease.
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Background
Anti-N-methyl-D-aspartate receptor (NMDAR) encephal-
itis is an autoimmune disorder of the central nervous
system (CNS) that predominantly affects young females
[1]. The progressive multistage development of psychiatric
and neurologic symptoms represents a typical clinical
manifestation of the disease [2]. This clinical entity was
first reported in 2007 in a group of women with ovarian
teratomas and paraneoplastic production of anti-NMDAR
antibodies [3]. Subsequently, it was demonstrated that this
clinical phenotype arises from antibody-mediated internal-
ization of NMDARs and that non-paraneoplastic produc-
tion of anti-NMDAR antibodies is also possible [4].
The immunopathogenesis of this disease has yet to be
fully elucidated, although B cells, but not T cells, have
been proposed to be involved [5]. Based on clinical ob-
servation, a model of early cerebrospinal fluid (CSF)
lymphocytosis and subsequent expansion of the immune
repertoire within the intrathecal compartment was sug-
gested [6], but immunological data supporting this
model are insufficient.
To contribute to the current knowledge regarding the
immune mechanisms that participate in anti-NMDAR
encephalitis, we studied the complex system of chemo-
kines and cytokines in CSF and sera from anti-NMDAR
encephalitis patients at different time-points of the dis-
ease. Chemokines and cytokines are produced by various
cell types and reflect complex immune processes. Chemo-
kines attract immune cells to sites of action and, thus,
might be responsible for the initial pleocytosis. We selected
the following chemokines: C-C motif ligand 2 (CCL2) for
monocytes, C-X-C motif ligand 8 (CXCL8) for neutrophils,
CXCL10 for T cells and CXCL13 for B cells. B cell-
activating factor (BAFF) was measured as a critical marker
of B cell activation and survival. Based on the understand-
ing that T helper (Th) cells might support B cell functions
[7], we measured the levels of cytokines that are associated
with Th cell function, including interferon γ (IFNγ), tumour
necrosis factor α (TNFα), interleukin (IL)4 and IL17A [8].
Additionally, the cytokine profile was determined by evalu-
ating the levels of IL2, IL7 and IL15, which participate in
the differentiation and survival of different subsets of
lymphocytes, particularly T cells [9].
Methods
Subjects
Nine Caucasian patients (age: median 13 years, range 7–26
years; sex: 8 females, 1 male) with non-paraneoplastic anti-
NMDAR encephalitis were included in this study. The
patients were diagnosed and/or treated at the Motol
University Hospital, Prague, Czech Republic.
The patients’ CSF and sera were positive for anti-
NMDAR antibodies at the time of diagnosis. Their
clinical status was defined using the modified Rankin
score (mRS). Magnetic resonance imaging of the brain,
electrophysiological studies and oncological assess-
ments were performed upon disease diagnosis, and the
oncological assessments were repeated every 6 months.
Seven of the nine patients underwent more than one CSF
and serum withdrawal during the follow-up period (median
12 months, range 5–26 months) (Fig. 1a).
The control group consisted of ten Caucasian patients
(age: median 12 years, range 8–18 years; sex: 8 females,
2 males) who underwent a single CSF and serum with-
drawal due to the following symptoms: headache (n = 5),
visual impairment (n = 2), anxiety (n = 2) or tics (n = 1).
The findings in CSF and sera from the controls were
within the normal range, and no anti-NMDAR anti-
bodies were detected.
This study was approved by the Ethical Committee at
the Motol University Hospital. Informed consent was
obtained from all participants.
Samples
In total, 27 paired CSF/serum samples from nine patients
and ten paired CSF/serum samples from ten controls were
tested. The patient samples were stratified into three
periods after the appearance of the first disease symptom:
period 1 (eight patients; time-point of sample collection:
median 40 days, range 4–60 days); period 2 (seven
patients; time-point of sample collection: median 173 days,
range 143–200 days) and period 3 (six patients; time-point
of sample collection: median 390 days, range 320–
776 days). Stratification of the samples according to
the mRS and the laboratory results is shown in Fig. 1a, b.
Anti-NMDAR antibodies in CSF and sera were detected
using commercial kits (anti-glutamate receptor [type
NMDA] IIFT, Euroimmun, Germany). This cell-based
assay enabled the qualitative detection of anti-NMDAR
antibodies in the samples; quantitative analysis was not
performed.
The routine analysis of CSF included determinations
of the following: cell count, protein levels, CSF/serum
albumin ratio, immunoglobulin (Ig)G and IgM levels
and oligoclonal band levels.
Aliquots of centrifuged CSF and serum samples were
immediately stored at −20 °C and thawed once before
use for chemokine and cytokine analysis.
Chemokine and cytokine detection
The concentrations of the chemokines CCL2, CXCL8
and CXCL10 and the cytokines IFNγ, IL2, IL4, IL7, IL15,
IL17A and TNFα were measured with Luminex multiple
bead technology according to the manufacturer’s in-
structions (ProcartaPlex Human Simplex Immuno-
assay, eBioscience, San Diego, CA, USA). The data
were collected using the Luminex-100 system (Luminex,
Austin, TX, USA). The BAFF and CXCL13 concentrations
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were determined via enzyme-linked immunosorbent assay
according to the manufacturer’s instructions using soft-
ware from R&D Systems (Minneapolis, MN, USA).
Data analysis and statistics
Statistical analyses were performed using GraphPad
PRISM, version 6.0 (GraphPad Software, La Jolla, CA,
USA). Non-parametric tests were used. The Wilcoxon
signed-rank test was used for pairwise comparisons of
the CSF and sera samples. The Kruskal-Wallis test was
performed to compare multiple groups of samples, and
Dunn’s multiple comparisons test was employed for post
hoc analysis. Patient no. 1 provided multiple samples at
different time-points in each period, and we used the
average values in each period for multiple-group compari-
sons. The correlations between the parameters were calcu-
lated using the Spearman correlation. A P value <0.05 was
considered to be significant.
Results
Clinical data
The clinical peak of the disease manifested within 30 days
of the first disease symptom onset in all of the patients
(median 23 days, range 6-30 days). Nevertheless, the dis-
ease severity varied among the patients. Notably, patient
nos. 1 and 6 differed markedly from the others (Fig. 1a).
Data from patient no. 1 are depicted separately in the text.
Patient no. 6 manifested only moderate symptoms of the
disease and was diagnosed and treated with a delay.
The recovery time lasted for months. The mRS signifi-
cantly decreased in period 2 (median mRS = 2) compared
to period 1 (median mRS = 4, P = 0.0006, Mann-Whitney
U test). Clinical improvement continued into period 3
(median mRS = 1), although this result was not significant.
Generally, the patients reached mRS ≤2 in a median time
of 3 months (range 1–25 months).
The therapies were initiated within 60 days of disease
onset in all cases except for patient no. 6 (median
21 days, range 6–320 days). The patients were treated as
recommended [1]. Intravenous steroids, plasma exchange
or high-dose intravenous immunoglobulins were the first
treatment choices. Three patients did not respond suffi-
ciently to the first-line immunotherapy and received a
second-line treatment (nos. 1, 8 and 9). Patient no. 1
remained in a coma and was treated with a monoclonal
antibody against CD52 (alemtuzumab) and with two doses
Fig. 1 Stratification of CSF samples and the laboratory data. a For 7/9 patients with anti-NMDAR encephalitis, two or more CSF and serum samples were
collected at different time-points. In total, we collected 27 paired CSF and serum samples from the patients during the 26-month observation period. The
clinical status (as defined by the mRS) was assigned to every sample, and the successive samples from the same patient are marked. All of the patients
except for no. 8 and no. 9 were treatment naïve in period 1. Patients nos. 1, 8 and 9 did not respond sufficiently to the first-line immunotherapy, and the
second-line treatment was planned. All of the patients in period 2 were already treated. Patient no. 6 was diagnosed late; she was the only treatment naïve
patient in period 3. b The samples from the patients were stratified into three periods (periods 1–3) after the appearance of the first disease symptom
x(days; median and range). The following common laboratory data are summarized in the table (percentage among all of the samples in the given period):
pleocytosis in CSF (as defined by leukocytes > 5/μL); oligoclonal bands (OCB) in CSF; and anti-NMDAR antibody (Abs) positivity in CSF and serum
(defined qualitatively)
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of intrathecal methotrexate followed by oral mycopheno-
late mophetil (Fig. 3a) [10]. None of the patients relapsed.
The patient data are summarized in Table 1.
Chemokine and cytokine assays
We analysed the complex system of chemokines and
cytokines in patient CSF and serum samples at three
previously defined periods compared to corresponding
control samples. Samples from period 1 were obtained
from 6/8 treatment naïve patients. The remaining samples
from period 1 were obtained from patients who responded
insufficiently to the first-line immunotherapy, and the
second-line treatment was planned (nos. 8 and 9). Samples
in periods 2 and 3 were from treated patients. Only one
sample in period 3 was from treatment naïve patient
(no. 6). Marked changes in the levels of chemokines
and cytokines were observed in the CNS compartment
but not in the peripheral blood (Fig. 2a–g). Important
overall differences between the CNS compartment and
the peripheral blood are summarized in Additional file 1:
Figure S1A–C.
Chemokine levels in CSF
The CSF CXCL10 and CXCL13 concentrations were
significantly increased during period 1 and the CXCL10
level remained significantly increased during period 2 in
the patients compared with the controls (Fig. 2a, b). This
cross-sectional study did not reveal any significant differ-
ences in the CXCL8 or CCL2 levels (data not shown).
T and B cell-related cytokines in CSF
INFγ, TNFα and IL17A: The CSF levels of these Th cell-
related cytokines were significantly increased at all periods
in the patients compared with the controls (Fig. 1c–e). IL7
and IL15: The CSF IL15 concentration remained also sig-
nificantly increased at all periods in the patients compared
Table 1 Patient data
Patients
Number 1 2 3 4 5 6 7 8 9
Sex F F F F M F F F F
Age of onset (years) 7 10 13 13 13 18 20 18 26
Follow-up (months) 25 12 26 13 1 1 6 12 5
Clinical features at the disease peak
Psychiatric features Yes Yes Yes Yes Yes Yes Yes Yes Yes
Cognitive dysfunction Yes Yes Yes Yes Yes Yes Yes Yes Yes
Seizures Yes No Yes Yes No Yes Yes Yes Yes
Movement disorder Yes Yes No Yes Yes No No Yes No
Autonomic dysfunction Yes No No No No No No Yes No
Coma Yes No No No No No No Yes No
Laboratory features at the disease diagnosis
MRI changes No No No Yes No No No No Yes
EEG changes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Disease course and therapy
Progression (days)a 28 15 28 17 6 16 30 29 29
Time to therapy (days)b 6 15 49 21 4 320 60 21 29
Recovery (days)c 750 43 91 72 30 320 36 150 85


























This table summarizes the clinical, laboratory and follow-up data of nine patients with non-paraneoplastic anti-NMDAR encephalitis who were included in this
study. Our clinical study was focused on the dynamic course of the disease over time (in days after the onset of the first disease symptom): atime to the peak in
disease severity (all of the patients reached their disease severity peak within 30 days, and despite receiving immunotherapy, patients nos. 1 and 8 progressed to
a mRS of 5); btime to first therapy administration (all of the patients except for patient no. 6 received therapy within 60 days); and ctime to clinical improvement
to a mRS ≤2 (the recovery time varied between the patients: median 85 days, range 30–750 days; patient no. 6 had a mRS of 2 at the time of diagnosis). dThe
therapy summary is indicated as follows: CPA cyclophosphamide, CS corticosteroids, IA immunoadsorption, MMF mycophenolate mophetil, MTX methotrexate, PE
plasma exchange, RTX rituximab
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with the controls (Fig. 2g). The CSF IL7 concentration
was slightly yet significantly increased during periods 2
and 3 in the patients compared with the controls (Fig. 2f).
BAFF, IL2, and IL4: This longitudinal study did not reveal
any significant differences in the CSF BAFF concentration.
The CSF IL2 and IL4 concentrations were generally below
their respective detection limits (data not shown).
Correlation of the investigated parameters in anti-NMDAR
encephalitis
We correlated the disease period with the clinical status
(mRS), pleocytosis and the levels of all of the investigated
chemokines and cytokines. Correlations between time and
the mRS (r = −0.41, P = 0.04) and the CSF leukocyte num-
bers (r = −0.46, P = 0.02) and chemokine levels (CXCL10:
r = −0.68, P = 0.0001; CXCL13: r = −0.75, P < 0.0001) were
observed. Additionally, CSF pleocytosis correlated with
the chemokine levels (CXCL10: r = 0.47, P = 0.02;
CXCL13: r = 0.40, P = 0.047, data not shown). Time did
not correlate with the levels of B or T cell-related cyto-
kines (BAFF, TNFα, IFNγ, IL17A, IL7 and IL15).
Single case study
Patient no. 1, a 7-year-old girl, represented a minor group
of patients that do not respond to common therapy guide-
lines and are in a high risk of death [1]. Despite an early im-
munotherapy, the disease progression lasted 28 days, and
subsequently, she remained in a coma for 344 days. Finally,
she recovered when a biological treatment that depleted B
and Tcell populations in peripheral blood was administered
Fig. 2 Chemokine and cytokine levels in CSF. The patient CSF chemokine and cytokine levels in each of the three previously defined periods
were compared with the corresponding control levels. The Kruskal-Wallis test (K-W) was used for multiple-group comparisons, and Dunn’s test
was employed for post hoc analysis (statistical significance is denoted as *P < 0.05, **P < 0.005 or ***P < 0.0005). Each sample in each period
belonged to one patient. Because patient no. 1 provided more than one sample per period, the average value for this patient was used for multiple-group
analysis; a special sign marks this value. Chemokines: a Increased CXCL10 levels were observed during periods 1 and 2 (K-W: 0.0005; Dunn’s: P< 0.0005 and
P< 0.05, respectively); b The CXCL13 level was increased only in period 1 (K-W: 0.0015; Dunn’s: P< 0.0005). Th cell-related cytokines: c The IFNγ, d TNFα and
e IL17A levels were significantly increased in the patients at all periods during the follow-up period compared with the controls (K-W IFNγ: 0.02, K-W TNFα:
0.02, K-W IL17A: 0.004; Dunn’s: P < 0.05, details provided in the figure). Cytokines important for T cell survival and function: f Increased IL7
levels were detected in periods 2 and 3 (K-W: 0.017; Dunn’s: P < 0.05). g A significant increase in the IL15 levels were observed at all periods
(K-W: 0.0013; Dunn’s: P < 0.05, details are provided in the figure)
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in combination with a cytostatic agent intrathecally (Fig. 3a).
We evaluated nine paired CSF and serum samples from
this patient, which were collected over a 25-month follow-
up period (Fig. 1a).
The initial three CSF samples reflected her rapid clinical
deterioration into a coma (mRS 1, 3 and 5). In particular,
pleocytosis progression (7/μL and 77/μL, respectively) and
markedly increased levels of all of the investigated chemo-
kines and cytokines were observed in the first two samples.
Interestingly, the increase in the CXCL10 levels preceded
the increase in the CXCL13 and BAFF levels, and these
concentrations were the highest among all patients. Pleocy-
tosis was not observed, and the chemokine and BAFF levels
were not increased in the five subsequent samples that were
collected during her coma (Fig. 3b, c). In contrast, the in-
creases in the CSF levels of T cell-related cytokines (INFγ,
TNFα and IL17A), IL7 and IL15 persisted through the
whole follow-up period (period 1–3, Fig. 2c–g). A transitory
decrease in T cell-related cytokine levels was observed after
the intrathecal application of methotrexate, shortly before
her clinical improvement (Fig. 3d).
Discussion
Immune mechanisms in anti-NMDAR encephalitis are
currently being intensively studied. Analysis of chemokine
and cytokine levels in a clinical context can contribute to
a better understanding of the immune processes this dis-
ease. Our study was focused on the complex spectrum of
chemokines and cytokines related to B and T cell func-
tions and their changes over the different clinical courses
of anti-NMDAR encephalitis. To our knowledge, no other
cytokine study in this disease has been published except
the one by Leypoldt and his colleagues [11].
The role of B cells in anti-NMDAR encephalitis has
already been demonstrated [5, 12, 13]; however, the
mechanism underlying their entry into the CNS compart-
ment is unclear. Moreover, the quantity of B cells is scarce
as T cells predominate in the CSF of healthy individuals
[14]. CXCL13 was designated as the major determinant
Fig. 3 Single case study. A 7-year-old girl represented the most com-
plicated patient in the group, and she remained in a coma for 344 days.
a The timeline (in months) of combined immunotherapy and sample
withdrawal is shown. She did not respond to the first- or second-line
immunotherapy (immunoglobulins = IVIG, plasma exchange = PE,
immunoadsorption = IA, rituximab = RTX, cyclophosphamide = CPA).
Then, she was experimentally treated with intravenous alemtuzumab
combined with two doses of intrathecal methotrexate (MTX) followed
by oral mycophenolate mophetil (MMF). Nine successive CSF samples
were collected during the 25-month follow-up period. The first two
samples anticipated the rapid clinical deterioration (mRS = 1 and 3).
The five subsequent samples were collected while she was in a coma
(mRS = 5), and the final two samples were collected during the
recovery period (mRS = 3 and 2). b The CSF levels of the chemokines
CXCL10 and CXCL13 and c of BAFF peaked at disease onset (period 1).
The increase in the CXCL13 levels preceded the increase in the CXC10
levels and was followed by rapid clinical deterioration. Subsequently, the
concentrations of these factors remained unremarkable despite her
coma, as illustrated by the interquartile ranges of the levels in the
controls. d In contrast, the CSF levels of Th cell-related cytokines
(IFNγ, TNFα and IL17A) were increased throughout the follow-up
period. The exception was observed in the sample after the first
dose of intrathecal methotrexate and intravenous alemtuzumab,
which was shortly before her clinical improvement. Then, the levels
of these cytokines increased again without any signs of clinical relapse.
The interquartile range of the levels of these cytokines in the controls
did not exceed 1.2 pg/mL
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for B cell recruitment to the CNS compartment during
neuroinflammation [15, 16]. We observed lower CXCL13
levels in the CNS compartment than in the peripheral
blood; however, these levels were increased in the patients
compared with the controls (Additional file 1: Figure
S1A). This chemokine binds to C-X-C receptor 5
(CXCR5) and reflects an antibody-mediated immunopa-
thology [17]. Alternatively, CXCL10 binds to CXCR3,
which is expressed on different subsets of T cells, includ-
ing memory Th1 cells [18, 19]. Notably, IFNγ induces
CXCR3 expression on antibody-producing memory B cells
[20] and integrates with an increased CXCL10 level to
promote the stimulation of B cells in the CNS compart-
ment during viral encephalomyelitis [21].
We showed marked changes in the CSF levels of T
and B cell-related chemokines (CXCL10 and CXCL13).
The significantly increased levels of these chemokines
were observed at the early stage of the disease when the
clinical symptoms were the most prominent (period 1,
Fig. 2a, b). Furthermore, these chemokine levels corre-
lated with CSF pleocytosis. Interestingly, the initial
CXCL10 and CXCL13 levels were the highest in the
most complicated patient during her rapid clinical de-
terioration (Fig. 3b). During the following periods, these
chemokine levels decreased (periods 2 and 3, Fig. 2a, b).
CXCL13 was recently proposed as a biomarker of the
treatment response in anti-NMDAR encephalitis [11]. Our
findings regarding CXCL10 and CXCL13 raised the ques-
tion of whether the initial levels of these chemokines could
be potential predictive biomarkers of disease severity.
B cells are expected to thrive in the CNS compartment
due to the BAFF levels [22], which were previously studied
in other B cell-associated CNS pathologies [23, 24]. Des-
pite this expectation, no significant differences in the
BAFF concentrations were detected in our study. The CSF
BAFF levels in patient no. 1 did not differ from those in
the other patients, except for an isolated peak, which pre-
ceded her coma (Fig. 3c).
Further, we hypothesized that T cells could be involved
in the disease immunopathogenesis. It was recently re-
ported that Th17 cells appear to be more efficient in sup-
porting B cell responses outside the germinal centres and
in promoting antibody production than their Th1 counter-
parts based on animal models [25]. IL17A was previously
studied in antibody-mediated CNS disorders, such as
neuromyelitis optica [26]. We investigated a set of spe-
cific cytokines that might reflect the involvement of T
cells in anti-NMDAR encephalitis. Indeed, we observed
a slight yet significant increase in the CSF levels of
INFγ, TNFα, IL17A, IL7 and IL15 in these patients.
These Th1-/Th17-related cytokines and the crucial
cytokine for T cell survival did not correlate with time
and remained elevated throughout the periods exam-
ined. Notably, the highest levels of these cytokines were
observed in the samples of the most complicated patient
(periods 1–3, Fig. 2c–g). The relevance of these findings is
currently unclear and warrants careful follow-up of patients
who are recovering from this disease.
Conclusions
Our investigation of chemokines and cytokines in the
CSF and sera of anti-NMDAR encephalitis patients sup-
ported the hypothesis that the disease immunopathology
is restricted to the CNS compartment. The dynamics of
CXCL10 and CXCL13 CSF levels further supported the
hypothesis that chemoattraction of the immune cells
dominates at the early stage of the disease. Our findings
regarding CXCL10, IFNγ, TNFα, IL17A and IL15 raise
the question of possible involvement of T cells in this
disease. The role of these cytokines in anti-NMDAR
encephalitis remains to be elucidated.
Additional file
Additional file 1: Figure S1. Chemokine and cytokine levels in CSF and
peripheral blood. The Wilcoxon signed ranked test was used for pairwise
analyses of the CSF and sera samples to detect differences between the
CNS compartment and the peripheral blood. The interesting differences
in the general chemokine and cytokine levels between the CNS compartment
and the peripheral blood are depicted. A) The CXCL10 concentration was
markedly higher in CSF than in serum, whereas B) the CXCL13 and D) BAFF
concentrations showed the opposite trend. Because patient No. 1 provided
more than 1 sample per period, the average value for this patient was used
for multiple-group analysis; a special sign marks this value. (TIF 79 kb)
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